Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).
Qamar J. Khan(University of Kansas Medical Center), Priyanka Sharma(University of Kansas Medical Center), Laura M. Spring(Massachusetts General Hospital), Mohammad Jahanzeb(21st Century Oncology (United States)), Anne O’Dea(University of Kansas Medical Center), Amanda L. Amin(University of Kansas Medical Center), Aditya Bardia(Harvard University), Mia Hard(The University of Kansas Cancer Center), X. Cynthia(Washington University in St. Louis), Kari B. Wisinski(University of Wisconsin Carbone Cancer Center), Jamie L. Wagner(University of Kansas), Gregory Crane(University of Kansas Medical Center), Meghna S. Trivedi(Columbia University), Sibel Blau(Rainier Clinical Research Center), Ruth O’Regan(University of Wisconsin Carbone Cancer Center), Onalisa Winblad(University of Kansas Medical Center), Yuan Yuan(City of Hope), Issam Makhoul(University of Arkansas for Medical Sciences), Manana Elia(University of Kansas Medical Center), Kevin Kalinsky(Emory University)
Cited by 68
Related Papers
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846